Nanoparticle-Mediated Gene Delivery to the Lung

  • Rajagopal Ramesh
Protocol
Part of the Methods in Molecular Biology™ book series (MIMB, volume 433)

Summary

Drug delivery, especially gene delivery to the lung, has been a challenge. Numerous gene delivery systems to the lung have been developed and tested in preclinical studies. However, only a few of them have been successfully tested in the clinic and shown promise. The reasons for failure to translate preclinical findings into clinical setting include inefficient gene delivery, toxicity, stability, and other factors related to scaling and manufacturing of the gene delivery vehicle. Therefore, there is a need for developing and testing of new gene delivery systems that can overcome some of the existing limitations. Preclinical studies from our laboratory using a cationic lipid (1,2-Dioleoyl-3-Trimethylammonium-Propane (DOTAP):cholesterol)-based nanoparticle have shown efficient and effective gene delivery to the lung especially to tumor-bearing lungs of mice. Based on the efficacy and toxicity studies observed in preclinical studies, we have recently initiated a Phase I clinical trial for systemic treatment of non-small cell lung cancer (NSCLC). In this clinical trial, a tumor suppressor gene encapsulated in the lipid-based nanoparticle will be delivered intravenously to determine the maximum-tolerated dose (MTD). The results from this clinical trial will provide a basis for conducting subsequent Phase II trial that will focus on determining toxicity and therapeutic efficacy. In this chapter, the details for the synthesis and testing of the lipid-based nanoparticle for systemic gene delivery to the lung with emphasis on lung cancer is provided.

Key Words

Lung cancer nanoparticle liposomes systemic gene delivery tumor suppressor genes. 
This is a preview of subscription content, log in to check access.

Notes

Acknowledgments

The author thanks past and present members of the laboratory for their contribution in the development and testing of nanoparticles for gene delivery to the lung. This work was supported in part by the W.M. Keck Gene Therapy grant, by the Texas Higher Education Coordinating Board ARP/ATP grant 003657-0078-2001, by a Career Development award from the University of Texas SPORE in Lung Cancer (P50 CA70907), and by a sponsored research agreement with Introgen Therapeutics, Inc.

References

  1. 1.
    Edwards, B.K., Brown, M.L., Wingo, P.A., Howe, H.L., Ward, E., Ries, L.A., Schrag, D., Jamison, P.M., Jemal, A., Wu, X.C., Friedman, C., Harlan, L., Warren, J., Anderson, R.N., and Pickle, L.W. (2005) Annual report to the nation on the status of cancer, 1975–2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97, 1407–1427.CrossRefPubMedGoogle Scholar
  2. 2.
    Greenlee, R., Murray, T., Bolden, S., and Wingo, P.A. (2000) Cancer statistics.CA Cancer J Clin 50, 7–33.CrossRefPubMedGoogle Scholar
  3. 3.
    Cuenca, A.G., Jiang, H., Hochwald, S.N., Delano, M., Cance, W.G., and Grobmyer, S.R. (2006) Emerging implications of nanotechnology on cancer diagnostics and therapeutics.Cancer Jun 22, 107, 459–466.Google Scholar
  4. 4.
    Kubik, T., Bogunia-Kubik, K., and Sugaisaka M. (2005) Nanotechnology on duty in medical applications.Curr Pharm Biotechnol 6, 17–33.PubMedGoogle Scholar
  5. 5.
    Yezhelyev, M.V., Gao, X., Xing, Y., Al-Hajj, A., Nie, S., and O’Regan, R.M. (2006) Emerging use of nanoparticles in diagnosis and treatment of breast cancer.Lancet Oncol 7, 657–667.CrossRefPubMedGoogle Scholar
  6. 6.
    Kaul, Z., Yaguchi, T., Kaul, S.C., and Wadhwa, R. (2006) Quantum dot-based protein imaging and functional significance of two mitochondrial chaperones in cellular senescence and carcinogenesis. Ann N Y Acad Sci 1067, 469–473.CrossRefPubMedGoogle Scholar
  7. 7.
    Kobayashi, H., Kawamoto, S., Brechbiel, M.W., Bernardo, M., Sato, N., Waldmann, T.A., Tagaya, Y., and Choyke, P.L. (2005) Detection of lymph node involvement in hematologic malignancies using micromagnetic resonance lymphangiography with a gadolinum-labeled dendrimer nanoparticle.Neoplasia 7, 984–991.CrossRefPubMedGoogle Scholar
  8. 8.
    Smith, A.M., Dave, S., Nie, S., True, L., and Gao, X. (2006) Multicolor quantum dots for molecular diagnostics of cancer.Expert Rev Mol Diagn 6, 231–244.CrossRefPubMedGoogle Scholar
  9. 9.
    Devalapally, H., Shenoy, D., Little, S., Langer, R., and Amiji, M. (2006) Poly(ethylene oxide)-modified poly(beta-amino ester) nanoparticles as a pH-sensitive system for tumor-targeted delivery of hydrophobic drugs: part 3. Therapeutic efficacy and safety studies in ovarian cancer xenograft model.Cancer Chemother Pharmacol Jul 22, 2007, 59, 477–404.CrossRefGoogle Scholar
  10. 10.
    Reddy, L.H., Vivek, K., Bakshi, N., and Murthy, R.S. (2006) Tamoxifen citrate loaded solid lipid nanoparticles (SLN): preparation, characterization, in vitro drug release, and pharmacokinetic evaluation.Pharm Dev Technol 11, 167–177.CrossRefPubMedGoogle Scholar
  11. 11.
    Farokhzad, O.C., Karp, J.M., and Langer, R. (2006) Nanoparticle-aptamer bioconjugates for cancer targeting.Expert Opin Drug Deliv 3, 311–324.CrossRefPubMedGoogle Scholar
  12. 12.
    Ramesh, R., Saeki, T., Templeton, N.S., Ji, L., Stephens, L.C., Ito, I., Wilson, D.R., Wu, Z., Branch, C.D., Minna, J.D., and Roth, J.A. (2001) Successful treatment of primary and disseminated human lung cancers by systemic delivery of tumor suppressor genes using an improved liposome vector.Mol Ther 3, 1–14.CrossRefGoogle Scholar
  13. 13.
    Ito, I., Ji, L., Tanaka, F., Saito, Y., Gopalan, B., Branch, C.D., Xu, K., Atkinson, E.N., Bekele, B.N., Stephens, L.C., Minna, J.D., Roth, J.A., and Ramesh, R. (2004) Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo.Cancer Gene Ther 11, 733–739.CrossRefPubMedGoogle Scholar
  14. 14.
    Gopalan, B., Ito, I., Branch, C.D., Stephens, C., Roth, J.A., and Ramesh, R. (2004) Nanoparticle based systemic gene therapy for lung cancer: molecular mechanisms and strategies to suppress nanoparticle-mediated inflammatory response.Technol Cancer Res Treat 3, 647–657.PubMedGoogle Scholar
  15. 15.
    Ramesh, R., Ito, I., Saito, Y., Wu, Z., Mhashikar, A.M., Wilson, D.R., Branch, C.D., Roth, J.A., and Chada, S. (2004) Local and systemic inhibition of lung tumor growth after nanoparticle-mediated mda-7/IL-24 gene delivery.DNA Cell Biol 23, 850–857.PubMedGoogle Scholar
  16. 16.
    Templeton, N.S., Lasic, D.D., Frederick, P.M., Strey, H.H., Roberts, D.D., and Pavlakis, G.N.(1997) Improved DNA:liposome complexes for increased systemic delivery and gene expression.Nat Biotechnol 15, 647–652.CrossRefPubMedGoogle Scholar
  17. 17.
    Ito, I., Began, G., Mohiuddin, I., Saeki, T., Saito, Y., Branch, C.D., Vaporciyan, A., Stephens, L.C., Yen, N., Roth, J.A., and Ramesh, R. (2003) Increased uptake of liposomal-DNA complex by lung metastases following intravenous administration.Mol Ther 7, 409–418.CrossRefPubMedGoogle Scholar
  18. 18.
    Ito, I., Saeki, T., Mohuiddin, I., Saito, Y., Branch, C.D., Vaporciyan, A., Roth, J.A., and Ramesh R. (2004) Persistent transgene expression following intravenous administration of a liposomal complex: role of IL-10 mediated immune suppression.Mol Ther 9, 318–327.CrossRefPubMedGoogle Scholar

Copyright information

© Humana Press, a part of Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Rajagopal Ramesh
    • 1
  1. 1.Department of Thoracic and Cardiovascular SurgeryThe University of Texas M.D.Anderson Cancer CenterTX

Personalised recommendations